Table 3. Univariate Cox regression analysis of oncologic outcomes.
| Variables | Category | DRFS | LRFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P-value | HR | 95% CI | P value | ||||
| NAT | Yes | 1.989 | (0.588–6.724) | 0.268 | 1.773 | (0.596–5.272) | 0.303 | 1.253 | (0.251–6.245) | 0.783 | ||
| Location | Gastric | 0.412 | (0.153–1.109) | 0.079 | 0.536 | (0.171–1.682) | 0.285 | 0.55 | (0.11–2.75) | 0.467 | ||
| Non-gastric | 1 | 1 | 1 | |||||||||
| Size, cm | ≤5 | 0.258 | (0.086–0.778) | 0.016* | 0.192 | (0.037–1.001) | 0.05 | 0.138 | (0.015–1.233) | 0.076 | ||
| 6–10 | 0.328 | (0.13–0.83) | 0.019* | 0.536 | (0.175–1.645) | 0.276 | 0.278 | (0.062–1.243) | 0.094 | |||
| >10 | 1 | 1 | 1 | |||||||||
| AT | Yes | 0.435 | (0.129–1.47) | 0.18 | 1.061 | (0.139–8.085) | 0.954 | 0.553 | (0.068–4.51) | 0.58 | ||
*, Denotes statistically significant. DRFS, distant recurrence-free survival; LRFS, local recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. NAT, neoadjuvant therapy; AT, adjuvant therapy.